SG Americas Securities LLC Decreases Position in Humana Inc. (NYSE:HUM)

SG Americas Securities LLC lessened its stake in Humana Inc. (NYSE:HUM - Free Report) by 60.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,828 shares of the insurance provider's stock after selling 4,250 shares during the period. SG Americas Securities LLC's holdings in Humana were worth $717,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of HUM. Creative Financial Designs Inc. ADV raised its stake in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock valued at $27,000 after buying an additional 61 shares during the last quarter. Atwood & Palmer Inc. bought a new position in shares of Humana during the third quarter worth $29,000. Ashton Thomas Securities LLC purchased a new position in shares of Humana in the third quarter valued at $31,000. Your Advocates Ltd. LLP lifted its stake in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock worth $32,000 after acquiring an additional 45 shares during the last quarter. Finally, LRI Investments LLC grew its stake in Humana by 1,021.4% in the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider's stock worth $50,000 after acquiring an additional 143 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company's stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of recent research reports. Morgan Stanley raised their price objective on Humana from $288.00 to $301.00 and gave the company an "equal weight" rating in a research report on Tuesday, December 17th. Bank of America raised Humana from an "underperform" rating to a "neutral" rating and increased their price target for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Deutsche Bank Aktiengesellschaft cut their price target on Humana from $349.00 to $250.00 and set a "hold" rating for the company in a research note on Thursday, October 3rd. Leerink Partnrs downgraded shares of Humana from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 2nd. Finally, UBS Group decreased their target price on shares of Humana from $380.00 to $250.00 and set a "neutral" rating on the stock in a research note on Friday, October 4th. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Humana currently has a consensus rating of "Hold" and an average target price of $297.68.

Humana Stock Performance

Shares of HUM stock traded up $2.65 on Thursday, reaching $296.88. The stock had a trading volume of 1,163,848 shares, compared to its average volume of 1,533,181. The firm has a market capitalization of $35.75 billion, a price-to-earnings ratio of 26.30, a P/E/G ratio of 2.15 and a beta of 0.55. The firm's 50-day moving average is $275.44 and its two-hundred day moving average is $303.07. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts' consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion during the quarter, compared to analysts' expectations of $28.66 billion. On average, research analysts expect that Humana Inc. will post 16.11 EPS for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.